Pramipexole in treatment-resistant depression: An extended follow-up

We evaluated the long‐term antidepressant safety and response of adjunctive pramipexole, a D2–D3 dopamine agonist, in the course of drug‐resistant depression. Twenty‐three patients with treatment‐resistant major depressive episode (MDE) were followed up after a 16‐week pramipexole add‐on trial. Pram...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Depression and anxiety 2004, Vol.20 (3), p.131-138
Hauptverfasser:	Cassano, Paolo, Lattanzi, Lorenzo, Soldani, Federico, Navari, Serena, Battistini, Giulia, Gemignani, Alfredo, Cassano, Giovanni Battista
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease Adult adverse effects Aged Benzothiazoles Depressive Disorder, Major - drug therapy dopamine agonists Dopamine Agonists - administration & dosage Dopamine Agonists - therapeutic use Drug Administration Schedule Drug Resistance Female Follow-Up Studies Humans investigational therapies Male Middle Aged mood disorders Prospective Studies Surveys and Questionnaires Thiazoles - administration & dosage Thiazoles - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!